Bialy Lukasz P, Wojcik Cezary, Mlynarczuk-Bialy Izabela
Private General Practice (Praktyka Lekarska dr n. med. Lukasz Bialy), Warsaw, Poland.
Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Jun;162(2):71-78. doi: 10.5507/bp.2018.022. Epub 2018 May 15.
Patients who are unable to receive oral medication (p.o.) are a major problem in outpatient settings, especially in home health care systems. Mucosal administration of drugs offers an alternative to the oral route, especially when the parenteral mode cannot be used. There are three main pathways of mucosal administration: sublingual/buccal, intranasal and rectal. We discuss the possibility of mucosal delivery of antihypertensive drugs. Perindopril arginine and Amlodipine besylate are registered in the EU as orodispersible tablets for oromucosal delivery, however, they are not available in all countries. For this reason, we describe other drugs suitable for mucosal delivery: Captopril and Nitrendipine in the sublingual system and Metoprolol tartrate, Propranolol and Furosemide by the transrectal route. Based on the published data and common clinical practice we discuss the use of mucosal delivery systems of all these antihypertensive drugs with special attention to their pharmacokinetics. We illustrate this mini-review with a case report of the prolonged-term use of mucosal delivery of sublingual Captopril and Nitrendipine combined with rectal Metoprolol tartrate and Furosemide in a patient with severe hypertension unable to receive medication p.o. This is also a report on the first human use of Furosemide-containing suppositories as well as prolonged-term transmucosal administration of these four drugs, describing a practical approach leading to successful control of severe hypertension with four antihypertensive drugs delivered via the mucosal route. The treatment was effective and without side effects; however, the long-term safety and efficacy of such therapy must be confirmed by randomized clinical trials.
无法口服给药(p.o.)的患者是门诊环境中的一个主要问题,尤其是在家庭医疗保健系统中。药物的粘膜给药提供了一种替代口服途径的方法,特别是在不能采用胃肠外给药方式时。粘膜给药有三种主要途径:舌下/颊部、鼻内和直肠。我们讨论了抗高血压药物粘膜给药的可能性。培哚普利精氨酸盐和苯磺酸氨氯地平在欧盟注册为口腔粘膜给药的口腔崩解片,然而,并非所有国家都有。因此,我们描述了其他适合粘膜给药的药物:舌下给药系统中的卡托普利和尼群地平,以及经直肠途径给药的酒石酸美托洛尔、普萘洛尔和呋塞米。基于已发表的数据和常见临床实践,我们讨论了所有这些抗高血压药物粘膜给药系统的使用,特别关注它们的药代动力学。我们用一个长期使用舌下卡托普利和尼群地平联合直肠酒石酸美托洛尔和呋塞米粘膜给药治疗一名无法口服药物的重度高血压患者的病例报告来说明这篇小型综述。这也是关于含呋塞米栓剂首次用于人体以及这四种药物长期经粘膜给药的报告,描述了一种通过粘膜途径成功控制重度高血压的实用方法。该治疗有效且无副作用;然而,这种疗法的长期安全性和有效性必须通过随机临床试验来证实。